Andreas Tiede/ResearchGate
Dec 8, 2025, 11:08
Andreas Tiede: This Will Change Hematology Forever
Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, shared on LinkedIn:
”This will change Hematology forever: the milder Aza/Ven combination is more effective and less harmful than the traditional 3+7 chemo regimen in fit AML patients.
Groundbreaking data at ASH2025”
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.
It aims to bring together hematology professionals from across the globe.
Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.
More from ASH25 featured in Hemostasis Today.
-
Oct 25, 2026, 05:30Denis Oduor: Whole Blood and Component Therapy in Clinical Practice
-
Oct 25, 2026, 02:18Dai H. Chung: Delivering Lyfgenia to Pediatric Patients With Sickle Cell Disease
-
Oct 25, 2026, 02:17Marilyn Baffoe-Bonnie: What Does It Mean to Be Cured of Sickle Cell Disease?
-
Oct 25, 2026, 02:15Tamara Stipcevic: A Hand-Powered Device for Rapid Blood Typing and Hematocrit Estimation
-
Oct 25, 2026, 02:14Rhonda Patrick: Microplastics Generate Damaging Free Radicals Simply by Contacting Water
-
Oct 25, 2026, 02:12Chokri Ben Lamine: Rilzabrutinib – Oral BTK Inhibitor for ITP
-
Oct 25, 2026, 02:12Michael H. Tomasson: Self-Experimentation That Revealed the Immune Mechanism of ITP
-
Oct 25, 2026, 02:10Nabiha Huq Saifee: Do You Help Make Platelet Transfusion Decisions Before Lumbar Puncture?
-
Oct 25, 2026, 02:09Sebastian Szmit: Congratulations to Isabelle Mahé on Her New Cardio-Oncology Paper